Centessa Pharmaceuticals plc (LON:0ACX)

Centessa Pharmaceuticals Statistics

Total Valuation

LON:0ACX has a market cap or net worth of GBP 1.55 billion. The enterprise value is 1.43 billion.

Market Cap	1.55B
Enterprise Value	1.43B

Important Dates

The next estimated earnings date is Wednesday, August 13, 2025.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+26.02%
Shares Change (QoQ)	+0.74%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	85.94M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	133.85
PB Ratio	5.20
P/TBV Ratio	5.20
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-8.25
EV / Sales	128.31
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-11.40

Financial Position

The company has a current ratio of 14.37, with a Debt / Equity ratio of 0.31.

Current Ratio	14.37
Quick Ratio	13.93
Debt / Equity	0.31
Debt / EBITDA	n/a
Debt / FCF	-0.73
Interest Coverage	-18.75

Financial Efficiency

Return on equity (ROE) is -74.44% and return on invested capital (ROIC) is -30.38%.

Return on Equity (ROE)	-74.44%
Return on Assets (ROA)	-28.58%
Return on Invested Capital (ROIC)	-30.38%
Return on Capital Employed (ROCE)	-38.87%
Revenue Per Employee	134,998
Profits Per Employee	-2.01M
Employee Count	77
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

In the past 12 months, LON:0ACX has paid 2.91 million in taxes.

Income Tax	2.91M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +53.22% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+53.22%
50-Day Moving Average	12.93
200-Day Moving Average	15.05
Relative Strength Index (RSI)	65.08
Average Volume (20 Days)	81

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.18

Income Statement

In the last 12 months, LON:0ACX had revenue of GBP 11.61 million and -173.25 million in losses. Loss per share was -1.41.

Revenue	11.61M
Gross Profit	11.61M
Operating Income	-151.50M
Pretax Income	-170.34M
Net Income	-173.25M
EBITDA	-151.26M
EBIT	-151.50M
Loss Per Share	-1.41

Balance Sheet

The company has 220.20 million in cash and 91.33 million in debt, giving a net cash position of 128.88 million.

Cash & Cash Equivalents	220.20M
Total Debt	91.33M
Net Cash	128.88M
Net Cash Per Share	n/a
Equity (Book Value)	298.95M
Book Value Per Share	2.24
Working Capital	250.40M

Cash Flow

In the last 12 months, operating cash flow was -125.40 million and capital expenditures -26,316, giving a free cash flow of -125.42 million.

Operating Cash Flow	-125.40M
Capital Expenditures	-26,316
Free Cash Flow	-125.42M
FCF Per Share	n/a

Margins

Gross Margin	100.00%
Operating Margin	-1,304.95%
Pretax Margin	-1,467.24%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LON:0ACX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-26.02%
Shareholder Yield	n/a
Earnings Yield	-11.15%
FCF Yield	-8.07%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0ACX has an Altman Z-Score of 4.01 and a Piotroski F-Score of 3.

Altman Z-Score	4.01
Piotroski F-Score	3